Thyroxine Increases Epidermal Growth Factor Levels in the Mouse Thyroidin Vivo*

Abstract

Immunoreactive epidermal growth factor (EGF) has been detected in the thyroid, which raises questions concerning the source of thyroidal EGF and what affects its levels. We therefore have examined the effects of manipulating thyroid function on the immunoreactive EGF levels in plasma, thyroid, submaxillary gland (SMG), and kidney of adult male BALB/c mice, and we also analyzed the prepro-EGF messenger RNA in these tissues. Groups of six mice received daily injection of T4 (1 microgram, 5 micrograms, or 25 micrograms) or bovine TSH (1 mU) for up to 14 days. The plasma EGF concentration was 0.31 +/- 0.01 ng/ml in control animals, and T4 (5 micrograms) decreased the plasma levels by about one-half within 1 week. The thyroidal EGF was 0.50 +/- 0.14 ng/mg protein in control animals, and T4 (5 micrograms) increased the thyroidal EGF 8-fold within 1 week. There was a negative correlation between plasma and thyroidal EGF concentration (r = -0.93, P less than 0.01). Increasing doses of T4 also increased the SMG EGF content, while plasma levels fell (r = -0.88, P less than 0.01). The TSH treatment did not significantly alter the plasma or tissue EGF levels. Studies on mRNA prepared from these three tissues, using the reverse transcription and the polymerase chain reaction, indicated that the prepro-EGF mRNA was present in thyroid, SMG, and kidney. In conclusion, it appears that at least some thyroidal EGF is synthesized in the thyroid. Our observations that T4 increases the level of intrathyroidal EGF in a dose- and time-dependent fashion, while plasma levels fall, suggest the possibility that intrathyroidal EGF represents a shortloop feedback for the autocrine and/or paracrine regulation of thyroid function.